Clinical Data Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis PharmaTimesLead candidate ETD001 delivers significant lung function improvementRespiratoryRead full story pharminent May 12, 2026 (Last updated: May 16, 2026) PharmaTimes Lead candidate ETD001 delivers significant lung function improvement Respiratory Read full story Post navigation Previous: Cellular Intelligence scoops up Novo’s Parkinson’s therapyNext: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
